{"ticker": {"uuid": "cfc96b07-c8a4-4446-a224-5b867f724c6a", "symbol": "9926", "name": "Akeso, Inc.", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer", "summary": "Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in NSCLC or Any Tumor Type MIAMI, August 12, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing ", "url": "https://finance.yahoo.com/healthcare/articles/ivonescimab-combination-chemotherapy-approved-china-132200149.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T13:22:00+00:00", "published_display": "12 Aug 2026 13:22", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.383, "duplicate_count": 1, "topics": ["Clinical Trials", "Fda Approval", "Fourth Quarter", "Oncology", "Pharma"]}, {"title": "Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer", "summary": "HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) (\"Akeso\" or the \"Company\") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), in combination with ivonescimab (the Company's PD-1/VEGF bispecific antibody), for the treatment of advanced breast cancer. This study aims to explore the potential of Akeso's \"IO2.0 + ADC2.0\" regimen in advanced breast cancer, with a particular focus on first-line treatment of HR+/HER2- breast cancer an", "url": "https://finance.yahoo.com/healthcare/articles/akeso-advances-io2-0-adc2-040500141.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T04:05:00+00:00", "published_display": "10 Aug 2026 04:05", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.203, "duplicate_count": 1, "topics": ["Biotech", "Breast Cancer", "Clinical Trials"]}], "by_tier": {"direct": [{"title": "Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer", "summary": "Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in NSCLC or Any Tumor Type MIAMI, August 12, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing ", "url": "https://finance.yahoo.com/healthcare/articles/ivonescimab-combination-chemotherapy-approved-china-132200149.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T13:22:00+00:00", "published_display": "12 Aug 2026 13:22", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.383, "duplicate_count": 1, "topics": ["Clinical Trials", "Fda Approval", "Fourth Quarter", "Oncology", "Pharma"]}, {"title": "Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer", "summary": "HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) (\"Akeso\" or the \"Company\") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), in combination with ivonescimab (the Company's PD-1/VEGF bispecific antibody), for the treatment of advanced breast cancer. This study aims to explore the potential of Akeso's \"IO2.0 + ADC2.0\" regimen in advanced breast cancer, with a particular focus on first-line treatment of HR+/HER2- breast cancer an", "url": "https://finance.yahoo.com/healthcare/articles/akeso-advances-io2-0-adc2-040500141.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T04:05:00+00:00", "published_display": "10 Aug 2026 04:05", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.203, "duplicate_count": 1, "topics": ["Biotech", "Breast Cancer", "Clinical Trials"]}], "industry": [], "sector": []}, "total_fetched": 2, "total_unique": 2, "total_relevant": 2, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 2, "unique_stories": 2, "duplicates_removed": 0, "relevant_stories": 2, "current_evidence": 2, "direct_evidence": 2, "eodhd_articles": 2, "eodhd": {"configured": true, "status": "healthy", "calls_used": 240, "call_budget": 500, "budget_used_pct": 48.0, "requests_made": 48, "last_success_at": "2026-08-13T07:45:12.873585+00:00", "newest_seen_at": "2026-08-13T07:10:37+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3268, "unmapped_mentions": 1822}, "status": "healthy"}, "sentiment_summary": {"positive": 2, "negative": 0, "neutral": 0, "score": 56, "raw_score": 64, "total": 2, "evidence_count": 2, "effective_articles": 1.83, "direct_story_count": 2, "industry_story_count": 0, "sector_story_count": 0, "story_count": 2, "source_count": 1, "source_concentration": 1.0, "direct_share": 100, "dispersion": 1, "confidence": 53, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-12T13:22:00+00:00", "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 58, "events": [{"event": "earnings", "label": "Earnings", "weight": 0.6, "count": 1}, {"event": "general", "label": "Market update", "weight": 0.6, "count": 1}], "positive_events": 2, "negative_events": 0, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 2, "unique_stories": 2, "duplicates_removed": 0, "relevant_stories": 2, "current_evidence": 2, "direct_evidence": 2, "eodhd_articles": 2, "eodhd": {"configured": true, "status": "healthy", "calls_used": 240, "call_budget": 500, "budget_used_pct": 48.0, "requests_made": 48, "last_success_at": "2026-08-13T07:45:12.873585+00:00", "newest_seen_at": "2026-08-13T07:10:37+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3268, "unmapped_mentions": 1822}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 100.0, "latest_week": "2026-08-07", "one_week_move": 6.4, "four_week_move": 2.8, "twelve_week_move": -16.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.645962, "market_dynamics_buy_signal": false, "relative_strength": -16.009328, "fair_value_gap": 24.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "positive", "expectation_probability": 59.5181, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.4% over one week, +2.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 56, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 2}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 1}, {"label": "Market update", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Evidence confidence", "value": "53/100", "tone": "neutral", "text": "1.83 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "58/100 classification confidence."}, {"label": "Company focus", "value": "2", "tone": "neutral", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "1/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+6.4% over one week, +2.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer"}], "updated_at": "2026-08-13T07:51:59.352537+00:00", "detail_intelligence": {"headline": "Price moving ahead of tone", "summary": "Balanced news tone is drawn from 2 fresh independent stories, including 2 company-specific items across 1 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 56, "display": "56", "tone": "neutral", "note": "Balanced news tone"}, {"label": "Evidence confidence", "value": 53, "display": "53", "tone": "neutral", "note": "building confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "2 direct stories"}, {"label": "Evidence agreement", "value": 99, "display": "99", "tone": "positive", "note": "1/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 23, "note": "1.83 effective stories"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 78, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 99, "note": "cross-story consistency"}, {"label": "Source independence", "value": 0, "note": "lower publisher concentration"}], "freshness": 78, "source_independence": 0, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 683.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 1, "score": 62, "tone": "positive", "x": 820.6, "y": 113.2, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 0, "score": null, "tone": "neutral", "x": 866.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 1, "score": 64, "tone": "positive", "x": 912.2, "y": 109.5, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "820.6,113.2 912.2,109.5", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Stable", "tone": "neutral", "recent_score": 64, "prior_score": 62, "delta": 2, "recent_count": 1, "prior_count": 1, "volume_delta": 0}, "freshness_buckets": [{"label": "Last 24 hours", "count": 1, "share": 50}, {"label": "1 to 3 days", "count": 0, "share": 0}, {"label": "4 to 7 days", "count": 1, "share": 50}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 2, "share": 100, "score": 63, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 1, "share": 50, "score": 64, "tone": "positive"}, {"label": "Market update", "count": 1, "share": 50, "score": 62, "tone": "positive"}], "topics": [{"label": "Clinical Trials", "count": 2, "share": 100}, {"label": "Pharma", "count": 1, "share": 50}, {"label": "Oncology", "count": 1, "share": 50}, {"label": "Fourth Quarter", "count": 1, "share": 50}, {"label": "Fda Approval", "count": 1, "share": 50}, {"label": "Breast Cancer", "count": 1, "share": 50}, {"label": "Biotech", "count": 1, "share": 50}], "supporting": [{"label": "Direct evidence", "text": "2 current stories are mapped specifically to 9926."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 99/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}, {"label": "Price disagreement", "text": "Price is moving more forcefully than the current news tone suggests."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer", "summary": "Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in NSCLC or Any Tumor Type MIAMI, August 12, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing ", "url": "https://finance.yahoo.com/healthcare/articles/ivonescimab-combination-chemotherapy-approved-china-132200149.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T13:22:00+00:00", "published_display": "12 Aug 2026 13:22", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.387, "duplicate_count": 1, "topics": ["Clinical Trials", "Fda Approval", "Fourth Quarter", "Oncology", "Pharma"]}, "article_count": 2, "updated_at": "2026-08-13T06:24:42.172191+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 156.0, "label": "13 Feb 2026", "close": 105.3, "index": 100.0}, {"x": 78.6, "y": 147.6, "label": "20 Feb 2026", "close": 109.1, "index": 103.6}, {"x": 115.3, "y": 152.5, "label": "27 Feb 2026", "close": 106.9, "index": 101.5}, {"x": 151.9, "y": 151.6, "label": "06 Mar 2026", "close": 107.3, "index": 101.9}, {"x": 188.6, "y": 145.2, "label": "13 Mar 2026", "close": 110.2, "index": 104.7}, {"x": 225.2, "y": 133.4, "label": "20 Mar 2026", "close": 115.6, "index": 109.8}, {"x": 261.8, "y": 109.7, "label": "27 Mar 2026", "close": 126.4, "index": 120.0}, {"x": 298.5, "y": 78.8, "label": "03 Apr 2026", "close": 140.5, "index": 133.4}, {"x": 335.1, "y": 83.9, "label": "10 Apr 2026", "close": 138.2, "index": 131.2}, {"x": 371.7, "y": 55.8, "label": "17 Apr 2026", "close": 151.0, "index": 143.4}, {"x": 408.4, "y": 98.3, "label": "24 Apr 2026", "close": 131.6, "index": 125.0}, {"x": 445.0, "y": 89.1, "label": "01 May 2026", "close": 135.8, "index": 129.0}, {"x": 481.7, "y": 93.1, "label": "08 May 2026", "close": 134.0, "index": 127.3}, {"x": 518.3, "y": 123.3, "label": "15 May 2026", "close": 120.2, "index": 114.2}, {"x": 554.9, "y": 131.2, "label": "22 May 2026", "close": 116.6, "index": 110.7}, {"x": 591.6, "y": 127.9, "label": "29 May 2026", "close": 118.1, "index": 112.2}, {"x": 628.2, "y": 181.6, "label": "05 Jun 2026", "close": 93.6, "index": 88.9}, {"x": 664.9, "y": 185.1, "label": "12 Jun 2026", "close": 92.0, "index": 87.4}, {"x": 701.5, "y": 194.9, "label": "19 Jun 2026", "close": 87.55, "index": 83.1}, {"x": 738.1, "y": 204.2, "label": "26 Jun 2026", "close": 83.3, "index": 79.1}, {"x": 774.8, "y": 162.3, "label": "03 Jul 2026", "close": 102.4, "index": 97.2}, {"x": 811.4, "y": 173.6, "label": "10 Jul 2026", "close": 97.25, "index": 92.4}, {"x": 848.1, "y": 193.1, "label": "17 Jul 2026", "close": 88.35, "index": 83.9}, {"x": 884.7, "y": 168.7, "label": "24 Jul 2026", "close": 99.5, "index": 94.5}, {"x": 921.3, "y": 180.9, "label": "31 Jul 2026", "close": 93.95, "index": 89.2}, {"x": 958.0, "y": 167.6, "label": "07 Aug 2026", "close": 100.0, "index": 95.0}], "sentiment_points": [{"x": 716.0, "y": 122.6, "label": "21 Jun 2026", "score": 54}, {"x": 717.3, "y": 122.6, "label": "22 Jun 2026", "score": 54}, {"x": 718.5, "y": 122.6, "label": "22 Jun 2026", "score": 54}, {"x": 719.2, "y": 122.6, "label": "22 Jun 2026", "score": 54}, {"x": 721.1, "y": 122.6, "label": "22 Jun 2026", "score": 54}, {"x": 726.0, "y": 122.6, "label": "23 Jun 2026", "score": 54}, {"x": 729.3, "y": 126.3, "label": "24 Jun 2026", "score": 52}, {"x": 731.1, "y": 126.3, "label": "24 Jun 2026", "score": 52}, {"x": 731.5, "y": 126.3, "label": "24 Jun 2026", "score": 52}, {"x": 739.0, "y": 124.5, "label": "26 Jun 2026", "score": 53}, {"x": 743.9, "y": 130.0, "label": "27 Jun 2026", "score": 50}, {"x": 744.5, "y": 130.0, "label": "27 Jun 2026", "score": 50}, {"x": 750.2, "y": 130.0, "label": "28 Jun 2026", "score": 50}, {"x": 751.0, "y": 130.0, "label": "28 Jun 2026", "score": 50}, {"x": 758.1, "y": 130.0, "label": "29 Jun 2026", "score": 50}, {"x": 772.9, "y": 130.0, "label": "02 Jul 2026", "score": 50}, {"x": 778.9, "y": 130.0, "label": "03 Jul 2026", "score": 50}, {"x": 797.9, "y": 130.0, "label": "07 Jul 2026", "score": 50}, {"x": 841.7, "y": 130.0, "label": "15 Jul 2026", "score": 50}, {"x": 846.7, "y": 130.0, "label": "16 Jul 2026", "score": 50}, {"x": 854.5, "y": 130.0, "label": "18 Jul 2026", "score": 50}, {"x": 871.8, "y": 130.0, "label": "21 Jul 2026", "score": 50}, {"x": 877.5, "y": 130.0, "label": "22 Jul 2026", "score": 50}, {"x": 880.5, "y": 130.0, "label": "23 Jul 2026", "score": 50}, {"x": 880.9, "y": 130.0, "label": "23 Jul 2026", "score": 50}, {"x": 881.7, "y": 130.0, "label": "23 Jul 2026", "score": 50}, {"x": 887.2, "y": 130.0, "label": "24 Jul 2026", "score": 50}, {"x": 887.9, "y": 130.0, "label": "24 Jul 2026", "score": 50}, {"x": 889.5, "y": 130.0, "label": "24 Jul 2026", "score": 50}, {"x": 901.4, "y": 115.3, "label": "27 Jul 2026", "score": 58}, {"x": 907.7, "y": 111.6, "label": "28 Jul 2026", "score": 60}, {"x": 915.1, "y": 109.8, "label": "29 Jul 2026", "score": 61}, {"x": 932.1, "y": 111.6, "label": "02 Aug 2026", "score": 60}, {"x": 944.4, "y": 111.6, "label": "04 Aug 2026", "score": 60}, {"x": 958.0, "y": 109.8, "label": "07 Aug 2026", "score": 61}], "price_path": "42.0,156.0 78.6,147.6 115.3,152.5 151.9,151.6 188.6,145.2 225.2,133.4 261.8,109.7 298.5,78.8 335.1,83.9 371.7,55.8 408.4,98.3 445.0,89.1 481.7,93.1 518.3,123.3 554.9,131.2 591.6,127.9 628.2,181.6 664.9,185.1 701.5,194.9 738.1,204.2 774.8,162.3 811.4,173.6 848.1,193.1 884.7,168.7 921.3,180.9 958.0,167.6", "sentiment_path": "716.0,122.6 717.3,122.6 718.5,122.6 719.2,122.6 721.1,122.6 726.0,122.6 729.3,126.3 731.1,126.3 731.5,126.3 739.0,124.5 743.9,130.0 744.5,130.0 750.2,130.0 751.0,130.0 758.1,130.0 772.9,130.0 778.9,130.0 797.9,130.0 841.7,130.0 846.7,130.0 854.5,130.0 871.8,130.0 877.5,130.0 880.5,130.0 880.9,130.0 881.7,130.0 887.2,130.0 887.9,130.0 889.5,130.0 901.4,115.3 907.7,111.6 915.1,109.8 932.1,111.6 944.4,111.6 958.0,109.8", "price_change": -5.0, "sentiment_change": 7, "latest_close": 100.0, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}